Sinopharm Group Co Stock Fundamentals
| X2S Stock | 2.56 0.01 0.39% |
Sinopharm Group Co fundamentals help investors to digest information that contributes to Sinopharm Group's financial success or failures. It also enables traders to predict the movement of Sinopharm Stock. The fundamental analysis module provides a way to measure Sinopharm Group's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Sinopharm Group stock.
Sinopharm |
Sinopharm Group Co Company Market Capitalization Analysis
Sinopharm Group's Market Capitalization is the total market value of a company's equity. It is one of many ways to value a company and is calculated by multiplying the price of the stock by the number of shares issued. If a firm has one type of stock its market capitalization will be the current market share price multiplied by the number of shares. However, if a company has multiple types of equities then the market cap will be the total of the market caps of the different types of shares.
Current Sinopharm Group Market Capitalization | 5.93 B |
Most of Sinopharm Group's fundamental indicators, such as Market Capitalization, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Sinopharm Group Co is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In most publications or references market cap is broken down into the mega-cap, large-cap, mid-cap, small-cap, micro-cap, and nano-cap. Market Cap is a measurement of business as total market value of all of the outstanding shares at a given time, and can be used to compare different companies based on their size.
| Competition |
Based on the recorded statements, the market capitalization of Sinopharm Group Co is about 5.93 B. This is much higher than that of the sector and significantly higher than that of the Market Capitalization industry. The market capitalization for all Germany stocks is notably lower than that of the firm.
Sinopharm Group Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Sinopharm Group's current stock value. Our valuation model uses many indicators to compare Sinopharm Group value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Sinopharm Group competition to find correlations between indicators driving Sinopharm Group's intrinsic value. More Info.Sinopharm Group Co is rated first in current valuation category among its peers. It is rated below average in price to book category among its peers . The ratio of Current Valuation to Price To Book for Sinopharm Group Co is about 17,951,703,753 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Sinopharm Group's earnings, one of the primary drivers of an investment's value.Sinopharm Market Capitalization Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Sinopharm Group's direct or indirect competition against its Market Capitalization to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Sinopharm Group could also be used in its relative valuation, which is a method of valuing Sinopharm Group by comparing valuation metrics of similar companies.Sinopharm Group is currently under evaluation in market capitalization category among its peers.
Sinopharm Fundamentals
| Current Valuation | 15.96 B | |||
| Price To Book | 0.89 X | |||
| Price To Sales | 0.11 X | |||
| Total Debt | 8.42 B | |||
| Price To Earnings To Growth | 49.43 X | |||
| Market Capitalization | 5.93 B | |||
| Total Asset | 335.41 B | |||
| Annual Yield | 0.29 % | |||
| Net Asset | 335.41 B |
About Sinopharm Group Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Sinopharm Group Co's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Sinopharm Group using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Sinopharm Group Co based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Sinopharm Stock Analysis
When running Sinopharm Group's price analysis, check to measure Sinopharm Group's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sinopharm Group is operating at the current time. Most of Sinopharm Group's value examination focuses on studying past and present price action to predict the probability of Sinopharm Group's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sinopharm Group's price. Additionally, you may evaluate how the addition of Sinopharm Group to your portfolios can decrease your overall portfolio volatility.